- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02184455
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
September 13, 2019 updated by: Dr. Paul F. Gratzer
A Feasibility Study of DermGEN Dermal Regeneration Scaffold for the Treatment of Diabetic Foot Ulcers
The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU).
This will be a one-arm prospective study.
It is hypothesized that DermGEN treatment will result in positive healing outcomes with no significant adverse effects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a one-arm prospective study.
This study in Halifax will be mirrored in one other participating health care center in Toronto, Ontario, Canada with each centre anticipated to enrol 5-10 patients for a total of 15-20 patients.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H3A7
- Queen Elizabeth II Health Sciences Center
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
A subject will be considered eligible to participate in this study if each of the following inclusion criteria is satisfied:
- Patient with documented stable Type I or II diabetes (HbA1C >7.0 within 1 month prior to Day 0).
- Patient's ulcer has been present for a minimum of 2 weeks as of Day 0.
- Study ulcer has healed <30% in size during the 2 weeks prior to Day 0.
- Ulcer area is ≥1 cm2 prior to debridement at Day 0 of study.
- Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule.
- Ulcer is free of necrotic debris and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0.
- Patient has adequate circulation to the foot as evidenced by palpable pulse or pulse detectable with Doppler ultrasound, and lack of visible cyanosis in skin bordering the ulcer.
- Female patients are not pregnant at time of, or during study.
- Patient and caregiver ready and willing to participate and comply with follow-up regime.
- Patient or legal representative has read and signed the Institutional Ethics Review Board approved informed consent form.
Exclusion Criteria:
A subject will not be considered eligible to participate in this study if any one of the following exclusion criteria is satisfied:
- Evidence of gangrene on affected foot.
- Ulcer is over Charcot deformity (fractures or dislocation).
- Ulcer is non-diabetic in etiology.
- Ulcer has tunnels or sinus tracts that cannot be completely debrided.
- Medical condition(s) that in the Investigator's opinion make the patient inappropriate for study
- Patient has/had malignant disease not in remission for 5 years or more
- Patient has acute or chronic hepatitis, cirrhosis, serum albumin <2.0 gm/dL, or has alkaline phosphatase or LDH at twice the normal upper limit
- Patient receiving oral or parenteral corticosteroids, immunosuppression or cytotoxic agents, or is anticipated to require such agents during study
- Patient received radiation therapy within 30 days of Day 0 of study
- Patient has AIDS or is infected with HIV
- Patient has participated in another study using investigational drug(s) or device within the previous 30 days
- Obvious clinical signs and symptoms of ongoing cellulitis or osteomyelitis
- Patient has any other condition which seriously compromises their ability to complete the study
- Patient has known allergies to antibiotics, such as penicillin and streptomycin
- Patient has a history of bleeding disorder
- Patient received elective osseous procedures to the study foot within 30 days prior to screening visit, except that patients whose DFU overlies an area of treated osteomyelitis may be included, providing there exists a suitable base for application of the DermGEN.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DermGEN Decellularized Dermal Matrix
DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
|
DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Wound Area Reduction Compared to Baseline
Time Frame: 4 weeks
|
Digital photography was utilized to capture the appearance and size of the ulcer at each visit.
In the photograph a measurement scale was shown beside the wound.
The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound.
For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With Complete Healing at Any Time Point
Time Frame: 20 weeks
|
Complete healing is defined as 100% epithelialization without drainage.
Digital photography was utilized to capture the appearance and size of the ulcer at each visit.
In the photograph a measurement scale was shown beside the wound.
The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound.
For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100.
|
20 weeks
|
Number of Patients With Adverse Events
Time Frame: 20 weeks
|
Reporting the number of patients participating in the study having adverse events
|
20 weeks
|
Number of Patients With Ulcer Reoccurrence in the Same Location After Complete Healing
Time Frame: 1 year
|
Number of patients that reported a reoccurrence of the ulcer in the same location after complete healing at 1 year post treatment.
|
1 year
|
Percent Change in Wound Size Compared to Baseline
Time Frame: 20 weeks
|
Digital photography was utilized to capture the appearance and size of the ulcer at each visit.
In the photograph a measurement scale was shown beside the wound.
The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound.
For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100.
Note 100% equals complete closure of the wound.
|
20 weeks
|
Percent Change in Wound Area From Baseline
Time Frame: 12 Weeks
|
change in area of wound in percent from initial presentation
|
12 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark Glazebrook, PhD,MD, Queen Elizabeth II Health Sciences Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
May 1, 2017
Study Completion (Actual)
May 1, 2017
Study Registration Dates
First Submitted
July 3, 2014
First Submitted That Met QC Criteria
July 8, 2014
First Posted (Estimate)
July 9, 2014
Study Record Updates
Last Update Posted (Actual)
September 24, 2019
Last Update Submitted That Met QC Criteria
September 13, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetic Neuropathies
- Foot Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Foot
- Foot Ulcer
Other Study ID Numbers
- DeCell-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Type II
-
Microbio Co LtdCompleted
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
Clinical Trials on DermGEN
-
University Health Network, TorontoNot yet recruiting
-
DeCell Technologies Inc.Canadian Institutes of Health Research (CIHR); Dalhousie University; Lakehead...Not yet recruitingDiabetes Mellitus | Diabetic Foot Ulcer | Wound; Foot | Wound of Skin | Tissue Injury | Ulcer Foot | Ulcer Healing | Non-healing WoundCanada